Last reviewed · How we verify
Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease
Approved treatments
- MultiHance 0.1 mmol/kg · Bracco Diagnostics, Inc
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease patent landscape — cliff calendar, originator estates, attackable patents
- Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease treatment landscape brief
- Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease treatment updates RSS
Frequently asked questions about Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease
What drugs treat Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease?
Tracked treatments include MultiHance 0.1 mmol/kg.
What is the treatment for Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease?
Standard treatment for Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease includes MultiHance 0.1 mmol/kg. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease patent cliff · Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease CI report
- Treatment: MultiHance 0.1 mmol/kg · Bracco Diagnostics, Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing